Dabigatran: How the drug company withheld important analyses

BMJ (Online)

Volumn 349, Issue , 2014, Pages

  Cohen, Deborah ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

DABIGATRAN; DABIGATRAN ETEXILATE; WARFARIN;

ANTICOAGULATION; ARTICLE; BLEEDING; CEREBROVASCULAR ACCIDENT; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUSTRY; DRUG INFORMATION; DRUG MARKETING; DRUG MONITORING; DRUG SAFETY; EMBOLISM; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HUMAN; LAW SUIT; LICENSING; PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK REDUCTION;

ANTITHROMBINS; BENZIMIDAZOLES; BETA-ALANINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG APPROVAL; DRUG INDUSTRY; DRUG MONITORING; EUROPE; HEMORRHAGE; HUMANS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84904634733     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.g4670     Document Type: Article

References (17)

1. NICE Implementation Collaborative. Consensus. Supporting local implementation of NICE guidance on use of the non-Vitamin K antagonist oral anticoagulants (NOACs) in non-valvular atrial fibrillation. www.nice.org.uk/ resource/CG180/pdf/c/cg180-atrial-fibrillation-nic-consensus-statement-on-the- use-of-noacs?id=gvyb3hjdqrcjtn6ytpwx3ydb64.
2. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation. Eur Heart J 2012;33:2719-47.
3. AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014 Mar 28. [Epub ahead of print.]
4. Skanes AC, Healey JS, Cairns JA, Dorian P, Gillis AM, McMurtry MS, et al. Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. Can J Cardiol 2012;28:125-36.
5. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004;329:15-9. (Pubitemid 38869995)
6. Cohen D. Concerns over data in key dabigatran trial. BMJ 2014;349:g4747.
7. FDA. FDA approves Pradaxa to prevent stroke in people with atrial fibrillation. Press release, 16 October 2010. www.fda.gov/newsevents/newsroom/ pressannouncements/ucm230241.htm.
8. Staton T. Pradaxa hits blockbuster mark, swelling Boehringer sales. FiercePharma 2012 Mar 24. www.fiercepharma.com/story/pradaxa-hits-blockbuster- mark-swelling-boehringer-sales/2012-04-24.
9. Moore TJ, Furberg TC. The safety risks of innovation: the FDA's expedited drug development pathway. JAMA 2012;308:869-70.
10. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51.
11. Heneghan C, Onakpoya I, Mahtani KR. Questions over dabigatran's key trial. BMJ 2014;349:g4560.
12. Moore TJ, Cohen MR, Mattison DR. Dabigatran, bleeding, and the regulators. BMJ 2014;349: g4517.
13. Committee for Medicinal Products for Human Use (CHMP), Pradaxa assessment report, 9 June 2011, EMA/CHMP/203468/2011.
14. Moore TJ, Cohen MR, Furberg CD. Anticoagulants the leading reported drug risk in 2012. QuarterWatch 2012 Quarter 4. www.ismp.org/quarterwatch/pdfs/ 2011Q4.pdf.
15. Reilly PA, Lehr T, Haertter S, Connolly SJ, Yusuf S, Eikelboom JW, et al. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients. J Am Coll Cardiol 2014;63:321-8.
16. Stangier J, Feuring M. Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrinolysis 2012;23:138-43.
17. Reilly PA, Connolly SJ, Yusuf S, Eikelboom JW, Ezekowitz MD, Wallentin L. Reply to Letter to the Editor: Regarding "The effect of dabigatran plasma concentrations ...." J Am Coll Cardiol 2014, doi:10.1016/j.jacc.2014.04. 012.